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HalofuginoneHalofuginone has been shown to prevent ﬁbrosis via the transforming growth factor-β/Smad3 pathway in
muscular dystrophies. We hypothesized that halofuginone would reduce apoptosis—the presumed cause of
satellite-cell depletion during muscle degradation—in themdxmouse model of Duchenne muscular dystrophy.
Six-week-old mdx mouse diaphragm exhibited fourfold higher numbers of apoptotic nuclei compared with
wild-type mice as determined by a TUNEL assay. Apoptotic nuclei were found in macrophages and in Pax7-
expressing cells; some were located in centrally-nucleated regenerating myoﬁbers. Halofuginone treatment of
mdxmice reduced the apoptotic nuclei number in the diaphragm, together with reduction in Bax and induction
in Bcl2 levels inmyoﬁbers isolated from thesemice. A similar effect was observedwhen halofuginonewas added
to culturedmyoﬁbers. No apparent effect of halofuginonewas observed inwild-typemice. Inhibition of apoptosis
or staurosporine-induced apoptosis byhalofuginone inmdxprimarymyoblasts and C2myogenic cell line, respec-
tively, was reﬂected by less pyknotic/apoptotic cells and reduced Bax expression. This reduction was reversed by
a phosphinositide-3-kinase and mitogen-activated protein kinase/extracellular signal-regulated protein kinase
inhibitors, suggesting involvement of these pathways in mediating halofuginone's effects on apoptosis.
Halofuginone increased apoptosis in α smooth muscle actin- and prolyl 4-hydroxylase β-expressing cells in
mdx diaphragm and in myoﬁbroblasts, the major source of extracellular matrix. The data suggest an additional
mechanism by which halofuginone improves muscle pathology and function in muscular dystrophies.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Adult skeletal myoﬁbers are terminally differentiated. Therefore, re-
generation after injury or in muscular dystrophies (MDs) depends on
recruitment of resident satellite cells. Upon appropriate stimulatory
signals, satellite cells are activated from the quiescent stage, undergo
proliferation and myogenic differentiation, and subsequently fuse with
pre-existing myoﬁbers or with other myoblasts, forming myotubes
whichmature into newmyoﬁbers [reviewed in 1,2]. Therefore, the sur-
vival and proliferative potential of satellite cells determine the regener-
ative capacity of skeletal muscles.
Studies have shown that myogenic differentiation is accompanied
by apoptosis [3–6]. However, a positive correlation between muscleMD; ECM, extracellular matrix;
′,6-diamidino-2-phenylindole;
r dystrophies; PI3K, phospho-
α smooth muscle actin; TGFβ,
es, The Hebrew University of
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).wasting and apoptotic signals was observed after acute stress, such
as electrical stimulation [7] and angiotensin II treatment [8], and in
chronic conditions such as myostatin-null mice [9], aging [10], cachexia
[11] and MDs [reviewed in 12,13]. In MDs, the muscle wasting due
to loss of myoﬁbers is accompanied by ﬁbrosis and muscle-function
failure. Necrosis is probably the major leading cause of myoﬁber degra-
dation in many MDs with sarcolemmal deﬁciencies, but in the mdx
mouse model of Duchenne MD (DMD), apoptosis precedes necrosis
[12–15]. Apoptotic nuclei were detected in dystrophic muscles, particu-
larly in interstitial cells such as macrophages and activated satellite
cells; however, some myoﬁbers with centrally located nuclei were
also TUNEL-positive, suggesting DNA fragmentation and apoptosis
[15]. Moreover, in themdxmouse model of DMD and in DMD patients,
upregulation of pro-apoptotic proteins such as Bax and caspases was
observed in myoﬁbers, suggesting that under pathological conditions,
these myoﬁbers undergo apoptosis [13,16,17]. Detection of apoptosis
and decreased Bcl2 expression have been observed in other MDs such
as Limb Girdle MD type 2C patients [18], and congenital MD type 1A
[5,19,20].
Halofuginone is a novel anti-ﬁbrotic agent which has been shown to
inhibit transforming growth factor β (TGFβ)-dependent ﬁbrosis in var-
ious animal models in which ﬁbrosis is the hallmark of the disease
[21–23, reviewed in 24]. Recently, halofuginone has been reported to
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ordination and balance in mouse models with early disease onset,
such as mdx and the laminin α2-deﬁcient dy2J/dy2J mouse model of
CMD [25,26], reviewed in [27]. Halofuginone also improvedmuscle his-
topathology and function in a dysferlin-knockout mouse model for
dysferlinopathy, a late-onset MD [28]. Moreover, halofuginone treat-
ment decreased muscle ﬁbrosis and improved lung and cardiac muscle
functions in oldermdxmicewith established ﬁbrosis [29]. In addition to
its effect on ﬁbrosis, halofuginone has a direct effect onmuscle cells and
promotes myotube fusion in primary myoblasts derived from normal
and dystrophic muscles [30].
The primary mechanism of halofuginone action is probably inhibi-
tion of Smad3 phosphorylation downstream of the TGFβ-signaling
pathway, as shown in various cell types [24,31–34], includingmyoblasts
derived from normal and dystrophic muscles [25–27,30]. It has been
suggested that halofuginone, via inhibiting Smad3 phosphorylation,
inhibits the differentiation of ﬁbroblasts into myoﬁbroblasts [24]; the
latter possess migratory capabilities and are the primary source for ex-
tracellular matrix (ECM) secretion during wound healing and ﬁbrosis
[35–37].
It has been reported that halofuginonepromotes the phosphorylation
of Akt and mitogen-activated protein kinase (MAPK) family members,
and enhances the association of Akt and MAPK/extracellular signal-
regulated protein kinase (MAPK/ERK) with the non-phosphorylated
form of Smad3, resulting in decreased Smad3 phosphorylation [30]. Re-
cently, halofuginone has been reported to reduce inﬂammation by acti-
vating the amino acid starvation response [38].
In this study, we investigated the role of halofuginone inmuscle-cell
survival of normal and dystrophic mice. We report that halofuginone
reduces the number of apoptotic nuclei in the mdxmouse diaphragm
in general, and that of Pax7-expressing satellite cells and macrophages
in particular, together with a reduction in Bax expression in both isolat-
edmyoﬁbers andmyoblasts, resulting in increasedmyoblast survival. In
addition, halofuginone increases apoptosis in myoﬁbroblasts, the major
source of extracellular matrix (ECM) in MD, suggesting an additional
muscle-function-enhancing mechanism.
2. Materials and methods
2.1. Reagents
Dulbecco's Modiﬁed Eagle's Medium (DMEM), sera and antibiotic–
antimycotic solution were purchased from Biological Industries. Colla-
genase and staurosporine were obtained from Sigma. Ly294002 and
UO127 were purchased from Calbiochem. TGFβ was purchased from
PeproTech Asia. Halofuginone bromohydrate was obtained from Halo
Therapeutics, LLC.
2.2. Mice
C57/BL/6J (Wt) andmdxmice were housed in cages under constant
photoperiod (12 L:12 D) with free access to food and water. The mice
were injected intraperitoneallywith either saline or 7.5 μg halofuginone
three times a week for 2 weeks, starting at 4 weeks of age. All animal
experiments were carried out according to the guidelines of the Volcani
Center Institutional Committee for Care and Use of Laboratory Animals
(IL-234/10).
2.3. Physiological parameters
Motor coordination and balance were evaluated with an accelerat-
ing single-station Rota-Rod treadmill (MedAssociates, Inc.) as previous-
ly described [25]. In brief, themicewere placed one at a time on the rod,
which was rotating at an initial speed of 3.5 rpm; the speed was gradu-
ally increased from 3.5 to 35 rpm over a period of 5 min, and the time
that the mice stayed on the rod was recorded. The mice were subjectedto three successive trials in each session, and the test was repeated on
two consecutive days. The performance of each mouse was measured
as the mean of its best individual performances over the three trials
on the second day.2.4. Cell preparation
Primary myoblasts and ﬁbroblasts from the diaphragm ofmdxmice
were prepared as described previously [30,39]. Primary cultures and
C2 myogenic cell line [40] were grown in DMEM supplemented with
20% (v/v) fetal calf serum. Cells were plated sparsely at 4 × 103 or 5 ×
104 cell/cm2 for C2 muscle cells and primary myoblasts and ﬁbroblasts,
respectively, for 1 day, after which themediumwas replaced with fresh
medium, with or without 10 nM halofuginone. In some cases cells were
immunostained for ﬁbroblast-speciﬁc protein1 using a monoclonal an-
tibody (Abnova, 1:100).2.5. Single-myoﬁber preparation and immunostaining
Single muscle myoﬁbers were isolated from the gastrocnemius
muscle of 6-week-old mdx and Wt mice, as described [41,42]. Brieﬂy,
mice were sacriﬁced and the gastrocnemius muscles were carefully
removed. The outer connective tissue was removed and the muscles
were immersed in a 2.5-ml solution of 0.28% (w/v) collagenase type I
in DMEM for 60 min for Wt mice or for 90 min for mdx mice. The
collagenase-treated muscle was then transferred into horse serum
(HS)-coated Petri dishes containing 10 ml of DMEM with 10% (v/v) HS
(growing medium) for full coverage of the digested ﬁbers, and triturat-
edwith awide-mouth pipette.Myoﬁberswere thenwashed three times
with 10 ml growing medium and placed in 90-mm coated plates. For
immunostaining, the myoﬁbers were transferred to 35-mm plates,
ﬁxed with 4% paraformaldehyde followed by incubation with Triton
X-100 (0.5% v/v in PBS) and blocking with 20% (v/v) goat serum in
PBS. The myoﬁbers were incubated with polyclonal anti-Bax (1:150,
Santa Cruz Biotechnology) and polyclonal anti-Bcl2 antibodies (1:150,
Calbiochem) overnight at 4 °C, followed by incubation with Alexa 594
goat anti-rabbit (1:300, Jackson) secondary antibody for 1 h at room
temperature, and nuclei were then stained with 4′,6-diamidino-2-
phenylindole (DAPI). The myoﬁbers were visualized under a ﬂuores-
cence microscope (Olympus) with a DP-11 digital camera (Olympus).2.6. TUNEL staining
TUNEL staining was performed with the MEBSTAIN Apoptosis Kit
Direct (Medical & Biological Laboratories Co.) according to the
manufacturer's protocol. This method detects nucleosome-sized DNA
fragments by tailing their 3′-OH ends with digoxigenin nucleotides
using terminal deoxynucleotidyl transferase (TdT). Parafﬁn-embedded
muscle sections were deparafﬁnized and rehydrated, then pretreated
with 20 μg/ml proteinase K for 20min at 37 °C. The slides were then in-
cubated with the TdT buffer containing the enzyme and FITC-labeled
nucleotides for 1 h to allow the tailing reaction to occur. After washes,
the slides were stained with DAPI. In case of double-immunostaining,
slides were immunostained with primary monoclonal antibody to β-
dystroglycan (1:50; Abcam) or to polyclonal antibodies to either Pax7
(1:100; Abcam), Bax (1:50), α smooth muscle actin (SMA, 1:100; Cell
Marque), prolyl-4 hydroxylase (P4Hβ, 1:100; Proteintech Group, Inc.),
macrophages (1:200; Acris Antibodies) followed by secondary Alexa
488 donkey anti-mouse or Alexa 594 goat anti-rabbit antibody (1:300;
Jackson), prior to the TUNEL staining. Sequential images of the entire di-
aphragm from ﬁve slides from each mouse (n= 5) were taken under a
ﬂuorescencemicroscope using DP-11 digital camera. The numbers of all
green-ﬂuorescent TUNEL-positive nuclei, DAPI nuclei or double-stained
cells were counted using CELL B software (Olympus).
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Microscopic observation and image acquisition were performed
with an Olympus IX 81 inverted confocal laser-scanning microscope
(Fluoview 500) equipped with a 405-nm diode laser, a 488-nm argon-
ion laser, a 543-nm helium–neon laser, and a 60 × 1.0 NA PlanApo
water-immersion objective. DAPI was excited at 405 nm and the emis-
sion was collected through a BA 430–460 ﬁlter; “GREEN”was excited at
488 nm and the emission was collected through a BA 505–525 ﬁlter;
“RED” was excited at 543 nm and the emission was collected through
a BA 560 IF ﬁlter. The transmitted-light images were obtained by
Nomarski differential interference contrast.2.8. Western blot analysis
Western blot analysis was performed as described previously [43].
Brieﬂy, equal amounts of protein were resolved by 10% SDS-PAGE and
then transferred to nitrocellulose membranes (Bio-Rad Laboratories).
After blocking, the membranes were incubated with the following pri-
mary polyclonal antibodies: rabbit anti-Bax (1:500), anti-Bcl2 (1:500),
and rabbit anti-Ying-Yang 1 antibody (YY1, 1:500, Santa Cruz Biotech-
nology). The transcriptional repressor protein YY1 was chosen because
its gene expression is not altered in the diaphragm of mdx mice after
halofuginone treatment [44].Fig. 1.Halofuginone reduces the number of apoptotic cells inmdxmuscle. (A) TUNEL stain
(a,c,e,g) halofuginone treatment (Halo; 7.5 μg/mouse, three times a week for 2 weeks, startin
analysis of TUNEL-positive nuclei presented as percentage of total DAPI-stained nuclei. (C) The
formance was observed in themdxmice that were halofuginone-treated (n = 6–8). *Signiﬁca2.9. Statistical analysis
The data were subjected to one-way analysis of variance (ANOVA)
and to all-pairs Tukey–Kramer HSD test using JMP® software [45].
3. Results
3.1. Halofuginone treatment reduces the number of apoptotic cells in mdx
mouse diaphragms
Six-week-oldmdxmouse diaphragmexhibited fourfold higher num-
bers of apoptotic cells compared withWtmice as determined by TUNEL
assay (Fig. 1Aa,c and B). Halofuginone treatment of 4-week-oldWtmice
for 2 weeks (7.5 μg, three times per week) did not change the percent-
age of apoptotic cells out of total nuclei in the diaphragm (Fig. 1Aa,b and
B). However, halofuginone treatment signiﬁcantly reduced the percent-
age of apoptotic cells in themdxmice (over twofold), returning to close
toWt levels (Fig. 1Ac,d and B). The reduction in the number of apoptotic
cells coincided with lower collagen levels in themdx diaphragms (data
not shown). Analysis of motor coordination and balance with Rota-Rod
demonstrated no difference in the performance of the Wt mice treated
or untreated with halofuginone (Fig. 1C). The mdx mice performed
poorly,while thehalofuginone-treatedmdxmice performed signiﬁcant-
ly better than the untreated mice as well as the Wt mice, in agreement
with previous studies [25].ing of diaphragms fromWt (a,b,e,f) andmdx (c,d,g,h) mice, with (b,d,f,h) or without
g at 3 weeks of age). Arrows point to TUNEL-positive nuclei. Bar, 25 μm. (B) Quantitative
effect of halofuginone onmotor coordination. A signiﬁcant enhancement in Rota-Rod per-
nt difference, within each mouse strain, at P b 0.05.
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A double-immunostaining of diaphragms derived from 6-week-old
mdx mice for TUNEL and for Pax7, a marker for satellite cells [1,2],
followed by quantitation analysis per total TUNEL-expressing nucleiFig. 2. Localization of apoptotic cells inmdxmouse diaphragm and the effect of halofuginone.
(D) of diaphragm sections derived from 6-week-oldmdxmice.White arrows point to TUNEL-po
analysis of cells positive for both, TUNEL and either Pax7,αSMA, P4Hβ ormacrophages presente
was observed between the groups at seven weeks of age (four weeks of treatment). *Signiﬁcanrevealed that the majority of the TUNEL-positive cells were satellite
cells (Fig. 2A and E). In some cells, the double-labeling of Pax7 and
TUNEL did not entirely merge with the partially degraded nucleus
(DAPI staining) (Supplement 1). This may be due to the nature of this
staining which may result from changes in antigen distributionDouble-immunostaining for TUNEL and Pax7 (A), αSMA (B), P4Hβ (C) and macrophages
sitive nuclei. Bar, 10 μM in A, B (mdx+ Halo), C and D; 20 μM in B (mdx). (E) Quantitation
d as ratio of total TUNEL-positive cells. (F) Motor coordination or balance on the Rota-Rod
t difference, within each protein (E) or group (F) (P b 0.05).
Fig. 2 (continued).
Fig. 3. Pro-apoptotic staining in diaphragms ofmdx andWtmice treated or untreatedwith
halofuginone (Halo). Mice were treated as described in Fig. 1 and immunostained for Bax
(red). Nuclei were stained with DAPI (blue). Note the high intensity levels of Bax inmdx
diaphragm section expression across the myoﬁbers, including in centrally-nucleated
ones (white arrows), which is diminished by halofuginone, while inWt mice Bax expres-
sion is barely noticed. Inner panel, a double-immunostaining for Bax and β-dystroglycan.
Bar 10 μM in inner panel.
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positive for TUNEL, either for macrophages (Fig. 2D) and to a lesser ex-
tent for α-SMA (Fig. 2B), and P4Hβ, a collagen cross-linking enzyme
(Fig. 2C), both proteins are highly expressed in myoﬁbroblasts [36,37,
44]; the latter cells exhibited approximately 15 to 20% of the total
TUNEL-positive cells (Fig. 2E). Halofuginone treatment of 4-week-old
mdx mice for 2 weeks signiﬁcantly reduced the number of TUNEL+/
Pax7+ cells out of total TUNEL-positive cells by almost twofold
(Fig. 2B and E), and that of TUNEL+/macrophage+ cells almost 30%
(Fig. 2D and E). Conversely, halofuginone treatment signiﬁcantly
enhanced the number of cells co-expressing TUNEL and αSMA and
P4Hβ out of total TUNEL+ cells by twofold and approximately 55%, re-
spectively (Fig. 2B, C and E).
3.3. Halofuginone enhances the survival of myoﬁbers
In light of the results from the TUNEL assay, we next tested the
expression of the pro-apoptotic protein, Bax in diaphragm sections
derived for 6-week-old Wt or mdx mice treated or untreated with
halofuginone. As expected, Bax expression was barely observed in Wt
diaphragms (Fig. 3) and was even further reduced by halofuginone.
High Bax expression was observed in almost all mdxmyoﬁbers includ-
ing the ones with central nuclei (i.e., regenerating myoﬁbers). A
double-immunostaining for Bax and β-dystroglycan, expressed at the
plasma membrane, revealed that Bax staining was with the myoﬁbers
(Fig. 3, inner panel). Halofuginone treatment profoundly reduced the
Bax levels almost back to those in the Wt.
The expression of the pro- and anti-apoptotic proteins, Bax and Bcl2,
respectively, was evaluated in single myoﬁbers derived from untreated
or halofuginone-treated mdx or Wt mice. Freshly prepared myoﬁbers
from gastrocnemius muscle were immediately ﬁxed and immuno-
stained with antibodies against either Bax or Bcl2, side by side, under
similar conditions. The proteins were expressed along the entire
myoﬁber. High levels of Bax protein were observed in myoﬁbers de-
rived from untreatedmdxmice compared while almost no Bax was ob-
served in the halofuginone-treated mice (Fig. 4Aa,b). Conversely, high
levels of Bcl2 were seen in myoﬁbers derived from halofuginone-
treated mice, in contrast to the minimal levels of expression in the
control myoﬁbers (Fig 4Ac,d). As in the tissue staining, no apparent dif-
ference in Bax or Bcl2 levels was observed between myoﬁbers derived
from halofuginone-treated and non-treated Wt mice (Fig. 4B).
3.4. Effect of halofuginone on myoﬁber and myoblast survival in culture
Our ﬁndings raised the possibility that halofuginone directly im-
proves the survival of muscle cells in mdx mice. To further investigate
the protective effect of halofuginone on these cells, myoﬁbers wereprepared from 6-week-old mdx mice and immediately incubated
in growing medium with or without 10 nM halofuginone for 24 h. The
myoﬁbers were ﬁxed and reacted with antibodies against Bax
and Bcl2. The non-treated myoﬁbers exhibited high levels of Bax
(Fig. 5Aa), whereas the halofuginone-treated myoﬁbers showed mark-
edly decreased levels (Fig. 5Ab). A reciprocal effect was observed with
regard to Bcl2; its levels were low in the untreated myoﬁber and
increased in response to halofuginone (Fig. 5Ac,d). No major effect of
halofuginonewas found on Bax and Bcl2 expression levels in myoﬁbers
isolated fromWt mice (data not shown), in agreement with the results
shown in Fig. 4B. A western blot analysis for Bax protein in mdx
myoﬁbers followed by densitometry (normalized to YY1) revealed
that halofuginone reduced Bax levels from 0.87 ± 0.25 arbitrary units
(AU) in untreated myoﬁbers to 0.48 ± 0.25 AU in treated ones (n =
4, P b 0.05).
The upregulation of Bax levels found in myoﬁbers derived frommdx
mice raised the possibility that their associated satellite cells undergo
apoptosis, which is reduced by halofuginone. To test this, primary myo-
blasts were prepared from the gastrocnemius ofmdxmice and incubat-
ed for 24 and 48 h in growing medium with or without halofuginone
(replaced daily), and then analyzed for Bax protein levels (Fig. 5B,
upper panel). Densitometry analysis revealed that while Bax levels
were similar at both time points in the control untreated myoblasts,
they were approximately twofold lower in the halofuginone-treated
cells (Fig. 5B). Bcl2 protein levels increased after 48 h of halofuginone
treatment (Fig. 5B, lower panel).
The effect of halofuginone in preventing apoptosis was observed in
mdx myoblasts and myogenic C2 cells treated with staurosporine.
Cells were plated with or without 10 nM halofuginone for 1 day, after
which staurosporine (0.5 μM) was added for an additional 13 h. Cells
were then ﬁxed, stained with DAPI and apoptotic/pyknotic nuclei
were scored by morphological criteria (Fig. 6A). In bothmdxmyoblasts
and myogenic C2 cells treated with staurosporine, numerous nuclei
with defragmented DNA (up to 40% of total nuclei) were observed.
Treatment of the cells with halofuginoneprior to staurosporine addition
Fig. 4. Pro- and anti-apoptotic protein staining in single myoﬁbers derived from gastrocnemius of untreated and halofuginone-treated (Halo)mdx (A) andWt (B) mice. Single myoﬁbers
were immunostained side by side for either Bax (a,b) or Bcl2 (c,d) under similar conditions. Nucleiwere stainedwithDAPI. Note the lower Bax andhigher Bcl2 intensity levels inmyoﬁbers
derived from halofuginone-treatedmdxmice and the reciprocal results in their untreated counterparts; there was no apparent change in the intensity levels of these two proteins in the
treated vs. untreated Wt mice.
Fig. 5.Direct effect of halofuginone on pro- and anti-apoptotic protein expression in vitro.
(A) Singlemyoﬁbers derived fromgastrocnemius of 6-week-oldmdxmicewere untreated
(a,c) or treated with 10 nM halofuginone (Halo) (b,d) for 24 h, and then stained for
Bax (a,b) and Bcl2 (c,d) under the conditions described in Fig. 3. Nuclei were stained
with DAPI. (B) Myoblasts derived frommdx diaphragms were untreated or treated with
halofuginone for 24 and 48 h. Bax and Bcl2 protein levels in cell lysates were analyzed
by western blot. Densitometry analysis was normalized to total YY1 and is presented as
fold Bax or Bcl2 induction relative to controls at each time point. The results represent
one out of three individual experiments.
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three- and twofold in the C2 andmdx cells, respectively (Fig. 6B). Addi-
tion of Ly294002 (25 μM), a stable phosphinositide-3 kinase (PI3K) in-
hibitor, or UO126 (10 μM), a speciﬁc inhibitor for MAPK/ERK signaling
pathway, 30 min prior to 24-h incubation with halofuginone to C2
cells reversed the halofuginone effect and increased the percentage of
pyknotic nuclei up to 60% and over 70% for Ly294002 and UO126, re-
spectively. In contrast to halofuginone's effect, addition of 10 μM TGFβ
for 48 h increased the percentage of pyknotic nuclei out of total nuclei
by almost threefold compared to non-treated cells in mdx myoblasts
(Fig. 6C).
The effect of the combined staurosporine and halofuginone treat-
ment on Bax levels of C2 cells was evaluated (Fig. 6D). Staurosporine
addition to C2 cells increased Bax levels more than twofold. Treatment
with halofuginone alone had no effect on Bax expression; however, it
prevented the staurosporine-induced Bax expression, with levels re-
maining comparable to those in untreated cells. Similar resultswere ob-
served for primarymdxmyoblasts treated with staurosporine (Fig. 6E).
Addition of Ly294002 to these cells prior to halofuginone treatment re-
versed the halofuginone-inhibited effect on Bax levels (Fig. 6F).
Due to its anti-ﬁbrotic properties, the effect of halofuginone on apo-
ptosis of ﬁbroblasts derived frommdxmuscle was tested. Halofuginone
increased the number of pyknotic/apoptotic nuclei threefold (Fig. 7A
and B), and immunostaining for a ﬁbroblast-speciﬁc marker, ﬁbroblast-
speciﬁc protein 1, revealed the identity of the pyknotic nuclei as that of
ﬁbroblasts (Fig. 7C). Bax protein levels were induced by more than
threefold relative to controls (Fig. 7D).4. Discussion
Apoptosis is one of the main causes of satellite-cell depletion in
chronic pathological conditions such as MDs. This study shows that
halofuginone, in addition to its capacity to reduce ﬁbrosis and inﬂam-
mation and improve muscle functions in MDs, is able to enhance the
survival of myoblasts and myoﬁbers in dystrophic mice.
In agreement with previous studies [14,46], less than 5% of the total
nuclei were apoptotic in the diaphragms of the Wt mice whereas in
themdxmice, at as early as 6 weeks of age, amuchhigher number of ap-
optotic nuclei was observed. These nuclei were identiﬁed as activated
satellite cells expressing Pax7—the majority of this cell population was
Fig. 6.Reduction of apoptosis by halofuginone in staurosporine-treatedmuscle cells. (A) C2muscle cells and primarymyoblasts derived frommdx diaphragmwere platedwithout (a,c) or
with (b,d) halofuginone (10 nM, Halo) for 1 day, afterwhich 0.5 μMstaurosporinewas added for an additional 13 h. Cells were then ﬁxed and stainedwith DAPI. Arrows indicate pyknotic/
apoptotic nuclei. (B) The apoptotic nuclei were counted and data are presented as percentage of total nuclei. To additional group of C2 cells, Ly294002 (Ly) and UO126 (UO) were added
30 min, prior to halofuginone addition (right panel). (C) mdx primary myoblasts were treated with or without TGFβ (1 ng/ml) for 48 h and cells were then ﬁxed and stained with
DAPI detected for pyknotic/apoptotic nuclei. Values are expressed asmeans± SE of three independent experiments inwhichmore than 2000 cells were examined. *Signiﬁcantly different
at P b 0.001 and P b 0.05 for B and C, respectively. (D) C2 muscle cells or mdx primary myoblasts (E) were treated with or without halofuginone as in A to induce apoptosis and with
staurosporine (St) for 6 h. Bax expression levelswere analyzed bywestern blot in cell lysates. (F)mdx primarymyoblasts were treatedwith orwithout halofuginone andwith andwithout
25 μMLy294002 (Ly) as described in B. Densitometry analysis for levels of Baxwas normalized to YY1 and is presented as fold induction relative to control at each time point, representing
one out of three individual experiments.
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mdx mice and DMD patients [15,17,47,48]. TUNEL-positive cells were
also observed in central-nucleus position in myoﬁbers, consistent with
the high Bax levels found in themuscle tissue and in isolated myoﬁbers
from these mice (Fig. 3), in agreement with previous studies in mdx
mice [49] and DMD patients [15], suggesting an apoptotic state of the
cells prior to degeneration and necrosis [14,48].
The present study shows for the ﬁrst time that halofuginone reduces
apoptosis in dystrophic mice. This was indicated by a marked reduc-
tion in the number of apoptotic Pax7- positive cells (i.e., satellite cells),Fig. 7.Halofuginone induces apoptosis inmdx ﬁbroblasts. Fibroblasts derived from6-week-oldm
after which cells were DAPI-stained for detection of pyknotic/apoptotic nuclei (A).White arrow
independent experiments in which more than 2000 cells were examined and presented as pe
speciﬁc protein1 (right panel) and DAPI (left panel), Bar, 50 μM. White arrows point to a pykn
malized to YY1 by densitometry and presented as fold induction relative to controls. 0, time zeas well as Bax levels in the diaphragms of halofuginone-treated mdx
mice, reaching close to those in the Wt. Moreover, single myoﬁbers
from the halofuginone-treated mdxmice exhibited lower levels of Bax
and higher levels of Bcl2 than myoﬁbers derived from non-treated
mice (Fig. 4A). These myoﬁbers were immunostained immediately
after their preparation and the protein levels likely reﬂect those
in vivo, supporting the idea that halofuginone is capable of reducing
the apoptotic state of myoﬁbers in vivo. This protective effect is not spe-
ciﬁc tomdxmice, as similar results were observed in dysferlin-knockout
mice (data not shown). Notably, halofuginone's reducing effect ondxmouse diaphragmwere incubatedwith orwithout 10nMhalofuginone (Halo) for 24 h,
s point to pyknotic nuclei. Pyknotic cells were quantiﬁed and data aremeans± SE of three
rcent of total nuclei (B). (C) Immunostaining of halofuginone-treated cells for ﬁbroblast-
otic nuclei. (D) Bax protein expression levels were detected by western blot analysis, nor-
ro; C, control; H, halofuginone.
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to the fact that the antibody used to mark the macrophages detects
both, M1 inﬂammatory macrophages and M2, macrophages playing a
major role in promotingmuscle growth and regeneration; both popula-
tions are present inmdxmice [50]. As expected, halofuginone did not af-
fect the numbers of apoptotic nuclei or Bax and Bcl2 levels in myoﬁbers
of the Wt mice, supporting our basic notion that the major efﬁcacy of
halofuginone lies in its ability to improve chronic pathological damage,
such as occurs in MDs.
The primary action of halofuginone is suggested to be reduction of
ﬁbrosis by attenuating the ﬁbroblast-to-myoﬁbroblast transition, as
has been demonstrated in numerous animal models, including MDs
[24,27–29]. It is plausible that the beneﬁcial effect of halofuginone on ﬁ-
broblast survival evolves from its inhibitory effect on ﬁbrosis. However,
the data here suggest that halofuginone also has a direct effect on
muscle-cell survival. Treatment of mdx-derived single myoﬁbers with
halofuginone in culture reduced the expression levels of Bax and in-
creased those of Bcl2. The number of pyknotic cells with apoptotic
phenotype and the level of Bax expression were lower in halofuginone-
treated primary mdx myoblasts than in untreated cells. Moreover, a
similar inhibitory effect of halofuginone on Bax levels was observed
in staurosporine-treated myoblasts, suggesting that at least in vitro,
halofuginone directly promotes muscle-cell survival.
Recent papers have reported that muscle-derived myoﬁbroblasts
from DMD patients show increased resistance to apoptosis [51]. These
cells are the main source of muscle collagen, as has been observed in
mdx [25,52], dy2j/dy2j [26] and dysferlin-knockout mice [28]. In this
study, we show that in contrast to its promotive effect on muscle-cell
survival, halofuginone treatment of mdx mice increases the apoptotic
number of the α-SMA and P4Hβ-expressing cells in the diaphragm
(Fig. 2) and number of pyknotic nuclei and Bax expression levels in
mdx-derived ﬁbroblasts (Fig. 7). Interestingly, a similar promotive effect
of halofuginone on myoﬁbroblast apoptosis was observed in pancreatic
tumors [44]. Taken together, the data suggest that halofuginone pro-
tects muscle cells while decreasing the number of myoﬁbroblasts by
inducing their apoptotic death; this implies a dual role for halofuginone
in this process, which is cell-type speciﬁc in muscle. These effects, along
with halofuginone's inhibitory effect on the ﬁbroblast-to-myoﬁbroblast
transition and subsequent ﬁbrosis, may provide an additional explana-
tion for the promotive effect of halofuginone on cardiac and skeletal
muscle functions in various MDs [25,26,28,29].
Whatmechanism(s) governs the opposite effects of halofuginone on
muscle cells and ﬁbroblasts with regard to apoptosis in dystrophic
mice? One mechanism might be inhibition of Smad3 phosphorylation
downstream of TGFβ, which has been shown to be halofuginone's ca-
nonical mode of action in both ﬁbroblasts and myoblasts [24,28,30,33,
34]. TGFβ is themajor activator of quiescentﬁbroblasts into differentiated
myoﬁbroblasts with migratory and ECM-production properties [53–55].
In contrast, TGFβ has been demonstrated to inhibit myoblast prolifera-
tion and differentiation [56–58], at least in part, via the Smad3 pathway
[59], and to induce apoptosis in vitro, as found in this and other studies
[60]. In light of these reports and our ﬁndings, it is highly likely that the
opposite effects of halofuginone on myoblast and ﬁbroblast apoptosis
are mediated by the same signaling pathway—the Smad3 pathway
downstream of TGFβ.
Halofuginonemay also protectmuscle cells via induction of Akt phos-
phorylation. Akt is considered a survival factor inmany cell types [61,62],
including skeletalmuscle cells [63], via its inhibition of pro-apoptotic sig-
nals such as Bad [64] andmembers of the FoxO family [65], or activation
of anti-apoptotic proteins suchasBcl2 [66]. Inmdxmice, Akt signaling at-
tenuated myoﬁber degradation, promoted myoﬁber regeneration and
improved muscle function [67]. Attenuation of halofuginone's effect on
the number of pyknotic nuclei and Bax expression in myoblasts by the
PI3K/Akt signaling pathway inhibitor Ly294002 suggests the involve-
ment of this pathway in mediating halofuginone-induced decrease of
apoptosis. Protection of staurosporine-induced apoptosis via activationof the PI3K/Akt signaling pathway was observed in cardiomyocytes
[68], which may explain in part the increase in cardiac function in mdx
mice after halofuginone treatment [25,29].
The inhibitory effect of halofuginone on Smad3 phosphorylation in
myoblasts [25,30] has been reported to be mediated, at least in part,
by phosphorylation of Akt and MAPK/ERK and their association with
the unphosphorylated form of Smad3 [30]. Halofuginone's survival ef-
fect onmyoblasts was reversed by theMAPK/ERK signaling pathway in-
hibitor UO126. MAPK/ERK pathway was reported to promote myoblast
cell survival by stabilizing the cyclin-dependent kinase inhibitor, p21
and inhibiting caspases 9 pro-activation [69]. Therefore, it may well be
thatMAPK/ERK andAkt signaling increasesmuscle-cell survival via a di-
rect effect on pro- and anti-apoptotic proteins, or indirectly via inhibi-
tion of Smad3 signaling, or both.
A link between Akt activation, apoptosis and improvement in mus-
cle functions has been observed in other MDs. Inhibition of apoptosis
in laminin-2-null mice increased Akt phosphorylation, decreased
inﬂammation, decreased levels of Bax protein and TUNEL-positive
myonuclei, and activated caspase-3, resulting in increased lifespan and
delayed onset of hind-limb paralysis [5,19,20]. The halofuginone-
induced decrease in apoptosis might provide a partial explanation for
the improved muscle histopathology and function observed in
laminin-α2-deﬁcient mice dy2J/dy2J mice [26].
In conclusion, our ﬁndings demonstrate the enhancing effect of
halofuginone on muscle-cell survival on the one hand, and ﬁbroblast
apoptosis on the other, suggesting an additional mechanism for
halofuginone's improved effect on histopathology andmuscle functions
in dystrophic mice.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.03.025.
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